Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease

被引：6
|
作者：
Sun, Yuechi [1 ]
He, Yan [1 ]
Liu, Yuan [1 ]
Shi, Guixiu [1 ]
机构：
[1] Xiamen Univ, Dept Rheumatol, Affiliated Hosp 1, Xiamen 361003, Peoples R China
来源：
CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2014年 / 15卷 / 06期
关键词：
Biologics; dermatomyositis; interstitial lung disease; polymyositis; IL-1 RECEPTOR ANTAGONIST; ANTI-SYNTHETASE SYNDROME; INFLAMMATORY MYOPATHIES; RITUXIMAB TREATMENT; THERAPY; ADULT; MYOSITIS; EFFICACY; MODEL;
D O I：
10.2174/138920101506140910145940
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.
引用
收藏
页码：521 / 524
页数：4
相关论文
共 50 条
  • [1] The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease
    Yumiko Sugiyama
    Ryusuke Yoshimi
    Maasa Tamura
    Mitsuhiro Takeno
    Yosuke Kunishita
    Daiga Kishimoto
    Yuji Yoshioka
    Kouji Kobayashi
    Kaoru Takase-Minegishi
    Toshiyuki Watanabe
    Naoki Hamada
    Hideto Nagai
    Naomi Tsuchida
    Yutaro Soejima
    Hiroto Nakano
    Reikou Kamiyama
    Takeaki Uehara
    Yohei Kirino
    Akiko Sekiguchi
    Atsushi Ihata
    Shigeru Ohno
    Shouhei Nagaoka
    Hideaki Nakajima
    Arthritis Research & Therapy, 20
  • [2] The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease
    Sugiyama, Yumiko
    Yoshimi, Ryusuke
    Tamura, Maasa
    Takeno, Mitsuhiro
    Kunishita, Yosuke
    Kishimoto, Daiga
    Yoshioka, Yuji
    Kobayashi, Kouji
    Takase-Minegishi, Kaoru
    Watanabe, Toshiyuki
    Hamada, Naoki
    Nagai, Hideto
    Tsuchida, Naomi
    Soejima, Yutaro
    Nakano, Hiroto
    Kamiyama, Reikou
    Uehara, Takeaki
    Kirino, Yohei
    Sekiguchi, Akiko
    Ihata, Atsushi
    Ohno, Shigeru
    Nagaoka, Shouhei
    Nakajima, Hideaki
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [3] THE PREDICTIVE PROGNOSTIC FACTORS FOR CLINICAL COURSE OF POLYMYOSITIS/DERMATOMYOSITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Sugiyama, Y.
    Yoshimi, R.
    Tamura, M.
    Hamada, N.
    Nagai, H.
    Tsuchida, N.
    Soejima, Y.
    Kunishita, Y.
    Kishimoto, D.
    Nakano, H.
    Kamiyama, R.
    Minegishi, K.
    Asami, Y.
    Kirino, Y.
    Ohno, S.
    Nakajima, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 645 - 645
  • [4] Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease
    Hozumi, Hironao
    Fujisawa, Tomoyuki
    Enomoto, Noriyuki
    Nakashima, Ran
    Enomoto, Yasunori
    Suzuki, Yuzo
    Kono, Masato
    Karayama, Masato
    Furuhashi, Kazuki
    Murakami, Akihiro
    Inui, Naoki
    Nakamura, Yutaro
    Mimori, Tsuneyo
    Suda, Takafumi
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (09) : 1394 - 1401
  • [5] miR-1 is a novel biomarker for polymyositis/dermatomyositis-associated interstitial lung disease
    Sugiyama, Yumiko
    Yoshimi, Ryusuke
    Takeno, Mitsuhiro
    Kunishita, Yosuke
    Kishimoto, Daiga
    Kamiyama, Reikou
    Kirino, Yohei
    Ohno, Shigeru
    Nakajima, Hideaki
    MODERN RHEUMATOLOGY, 2020, 30 (05) : 878 - 883
  • [6] Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease
    Gui, Xianhua
    Li, Wangzhong
    Jiang, Hanyi
    Wang, Rujia
    Yu, Min
    Zhao, Tingting
    Ma, Miao
    Ding, Jingjing
    Jin, Ziyi
    Qiu, Yuying
    Qiu, Xiaohua
    Zhang, Yingwei
    Cao, Min
    Huang, Mei
    Cao, Mengshu
    Dai, Jinghong
    Cai, Hourong
    Xin, Xiaoyan
    Xiao, Yonglong
    RMD OPEN, 2024, 10 (02):
  • [7] Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease
    Hozumi, Hironao
    Fujisawa, Tomoyuki
    Nakashima, Ran
    Johkoh, Takeshi
    Sumikawa, Hiromitsu
    Murakami, Akihiro
    Enomoto, Noriyuki
    Inui, Naoki
    Nakamura, Yutaro
    Hosono, Yuji
    Imura, Yoshitaka
    Mimori, Tsuneyo
    Suda, Takafumi
    RESPIRATORY MEDICINE, 2016, 121 : 91 - 99
  • [8] Treatment of amyopathic dermatomyositis-associated interstitial lung disease
    Xiao, Ting
    Xiao, Ting
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB72 - AB72
  • [9] Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease
    Chen, Zhiwei
    Wang, Xiaodong
    Ye, Shuang
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (03): : 291 - 293
  • [10] The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
    Sugiyama, Yumiko
    Yoshimi, Ryusuke
    Tamura, Maasa
    Hamada, Naoki
    Nagai, Hideto
    Tsuchida, Naomi
    Kunishita, Yosuke
    Soejima, Yutaro
    Kishimoto, Daiga
    Kamiyama, Reikou
    Minegishi, Kaoru
    Kirino, Yohei
    Ohno, Shigeru
    Nakajima, Hideaki
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345